View Cart

Photobiomodulation as a Treatment in Dry AMD - LumiThera EU

Doctors and patients have found this new mode of therapy beneficial.

By Hakan Kaymak, MD; and Hartmut Schwahn, PhD

The development of innovative treatments for debilitating diseases such as age-related macular degeneration (AMD) is crucial to advance patient care and to reduce burdens on patients, caregivers, and physicians. The dry, or nonexudative, form of AMD affects approximately 85% to 90% of individuals with AMD, and, until now, there have been no approved treatments for this condition aside from nutritional supplementation.

The Valeda Light Delivery System (LumiThera) was designed as a safe, multiwavelength platform for photobiomodulation (PBM). The device received the CE Mark in the European Union, where its indicated uses include treatment of ocular damage and disease using PBM, including inhibition of inflammatory mediators, edema, or drusen deposition; improvement of wound healing following ocular trauma or surgery; and increase in visual acuity and contrast sensitivity in patients with degenerative diseases such as dry AMD.

Read the full article on retinatoday.com

Posted on June 14th, 2020 in Articles | Comments Off on Photobiomodulation as a Treatment in Dry AMD
Posted by Clark Tedford

Comments are closed.